A meeting Monday between former Rep. Harold Ford (D-Tenn.) — who is considering a primary challenge against Sen. Kirsten Gillibrand (D-N.Y.) — and NARAL Pro-Choice New York officials solidified the group’s decision to endorse Gillibrand in a potential fall primary, the AP/WKRG reports…
No Comments »
Filed under: Women's Health
While Tim and Pam Tebow’s story “certainly is moving, … as a guide to making abortion decisions, it’s misleading,” Slate columnist William Saletan writes of Focus on the Family’s planned antiabortion-rights Super Bowl advertisement…
No Comments »
Filed under: Women's Health
Researchers in England are reporting that they have been able to establish limited communication with a man in a persistent vegetative state by using functional magnetic resonance imaging (fMRI).
No Comments »
Filed under: General Health News
Patients are more actively managing their healthcare through computer and Internet use, the first National Health Interview Survey to collect data on health information technology said.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — Still engaged in an intensely partisan debate over healthcare reform, the White House is ready to launch an initiative that’s likely to have widespread backing: a push to combat obesity.
No Comments »
Filed under: General Health News
Some genomic tests aimed at identifying patients most likely to respond to cancer drugs won a thumbs-up from a Medicare advisory panel, but others didn’t make the grade.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — The FDA has approved the first drug for the progressive hand disease known as Dupuytren’s contracture — the injectable collagenase clostridium histolyticum (Xiaflex).
No Comments »
Filed under: Pharmacy News
Tanezumab, a humanized monoclonal antibody that targets nerve-growth factor, reduced pain in three common pain conditions, according to the results from three phase two studies presented today in a single poster at the American Academy of Pain Medicine’s 26th Annual Meeting.
No Comments »
Filed under: Pharmacy News
Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company’s enzyme replacement therapy (ERT) in development for the treatment of Type 1 Gaucher disease, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.
No Comments »
Filed under: Pharmacy News
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a [...]
No Comments »
Filed under: Pharmacy News
